• PegBio posted an operating loss of RMB 214.23 million for the six months ended June 30, 2026, worsening from RMB 92.14 million.
• Net loss widened to RMB 216.2 million from RMB 93.67 million; basic and diluted loss per share deepened to RMB 0.55 from RMB 0.25.
• Adjusted net loss (non-HKFRS) increased to RMB 181.75 million from RMB 51.1 million, excluding RMB 34.45 million in share-based compensation.
• R&D expenses jumped to RMB 109.81 million from RMB 26.29 million, due to higher third-party services and AI-enabled R&D platform investment.
• Commercialization advanced for Paidakang (PB-119) with a first royalty payment of about HK$ 61 million; a second payment of about HK$ 49 million is expected.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pegbio Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12297567), on August 25, 2026, and is solely responsible for the information contained therein.